TITLE

Pneumococcal vaccine gets go-ahead in child schedule

AUTHOR(S)
Wilkinson, Emma; Pedder, Cato
PUB. DATE
January 2005
SOURCE
Pulse;1/8/2005, Vol. 65 Issue 1, p12
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the inclusion of a pneumococcal vaccine to the childhood immunization schedule in Great Britain. Agreement of the Joint Committee on Vaccination and Immunisation on the pneumococcal vaccination; Difficulties in the introduction of the vaccine; Benefits of the vaccine. INSETS: The annual burden of disease the vaccine may prevent;Options for pneumococcal vaccine schedule.
ACCESSION #
15668427

 

Related Articles

  • Child vaccine delayed by six months.  // Pulse;6/1/2006, Vol. 66 Issue 22, p2 

    The article reports that general practitioner negotiators have warned that pneumococcal vaccination will not be introduced into the childhood schedule in Great Britain until the end of 2006 at the earliest. The warning is confirmation that the vaccine will be delayed from its proposed...

  • Differential Effects of Pneumococcal Vaccines against Serotypes 6A and 6C. Park, In H.; Moore, Matthew R.; Treanor, John J.; Pelton, Stephen I.; Pilishvili, Tamara; Beall, Bernard; Shelly, Mark A.; Mahon, Barbara E.; Nahm, Moon H. // Journal of Infectious Diseases;12/15/2008, Vol. 198 Issue 12, p1818 

    Background. Because classic pneumococcal serotyping methods cannot distinguish between serotypes 6A and 6C, the effects of pneumococcal vaccines against serotype 6C are unknown. Pneumococcal vaccines contain serotype 6B but not serotypes 6A and 6C. Methods. We used a phagocytic killing assay to...

  • Pneumococcal surveillance in Malaysia and the need for carriage studies. McNeil, Hannah C.; Clarke, Stuart C. // International E-Journal of Science, Medicine & Education;2015, Vol. 9 Issue 2, p1 

    The authors discuss issues concerning the prevalence of pneumococcal disease in Malaysia. They highlight the implementation of epidemiological surveillance and the need to conduct carriage studies in the country. They also discuss the recommendation from the World Health Organization to include...

  • Polysaccharide pneumococcal vaccines. Jefferson, Tom // BMJ: British Medical Journal (International Edition);8/10/2002, Vol. 325 Issue 7359, p292 

    Editorial. Discusses polysaccharide pneumococcal vaccines, which is used to prevent infection with Streptococcus pneumoniae (pneumococcus). Epidemiology of pneumococcal disease; Effectiveness of the vaccines; Possibility that protein conjugate pneumococcal vaccines show clearer effectiveness;...

  • New Childhood Vaccine Targets Meningitis, Other Infections.  // FDA Consumer;May/Jun2000, Vol. 34 Issue 3, p4 

    Introduces the Prevnar Pneumococcal 7-valent Conjugate Vaccine, a vaccine to help protect infants from pneumococcal diseases; Cause of the disease; Pneumococcal bacteremia incidence in the United States; Comparison of Prevnar with other childhood vaccines; Side effects of the vaccine.

  • A strategy for prevention. Kassianos, George // Pulse;6/25/2005 Supplement, Vol. 65, p6 

    Focuses on the effectiveness of pneumococcal polysaccharide vaccine (PPV) in preventing invasive pneumococcal disease in adults in Great Britain. Joint Committee on Vaccination and Immunisation's recommendation of vaccination for individuals over the age of 65; Vaccination policy in Scotland and...

  • Increased Risk of Hospitalization for Acute Lower Respiratory Tract Infection among Australian Indigenous Infants 5-23 Months of Age Following Pneumococcal Vaccination: A Cohort Study. O'Grady, Kerry-Ann F.; Lee, Katherine J.; Carlin, John B.; Torzillo, Paul J.; Chang, Anne B.; Mulholland, E. Kim; Lambert, Stephen B.; Andrews, Ross M. // Clinical Infectious Diseases;4/1/2010, Vol. 50 Issue 7, p970 

    Background. Australian Indigenous children are the only population worldwide to receive the 7-valent pneumococcal conjugate vaccine (7vPCV) at 2, 4, and 6 months of age and the 23-valent pneumococcal polysaccharide vaccine (23vPPV) at 18 months of age. We evaluated this program's effectiveness...

  • New Recommendations for 13-Valent Pneumo Vaccine in Compromised Adults. Scully, Mary-Louise // Travel Medicine Advisor;Oct2012, Vol. 22 Issue 10, p53 

    New recommendations have been approved for the use of 13-valent pneumococcal conjugate vaccine in conjunction with the 23-valentpolysaccharide pneumococcal vaccine in immunocompromised adults ages 19 and older.

  • The roles of transition metals in the physiology and pathogenesis of Streptococcus pneumoniae. Honsa, Erin S.; Johnson, Michael D. L.; Rosch, Jason W. // Frontiers in Cellular & Infection Microbiology;Dec2013, Vol. 3 Issue 12, p1 

    For bacterial pathogens whose sole environmental reservoir is the human host, the acquisition of essential nutrients, particularly transition metals, is a critical aspect of survival due to tight sequestration and limitation strategies deployed to curtail pathogen outgrowth. As such, these...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics